PCDH17, protocadherin 17, 27253

N. diseases: 51; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 PosttranslationalModification group BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.030 PosttranslationalModification group BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0279680
Disease: Transitional cell carcinoma of bladder
Transitional cell carcinoma of bladder 		0.010 PosttranslationalModification disease BEFREE Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. 24567353 2014
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE PCDH17 methylation in tumor samples after radical prostatectomy may be used as an independent prognostic biomarker. 25091018 2014
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 PosttranslationalModification disease BEFREE PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). 25091018 2014
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.040 PosttranslationalModification phenotype BEFREE PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). 25091018 2014
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 PosttranslationalModification disease BEFREE In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer. 25091018 2014
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.010 PosttranslationalModification disease BEFREE In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer. 25091018 2014
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.040 Biomarker phenotype BEFREE Loss of protocadherin-17 (PCDH-17) promotes metastasis and invasion through hyperactivation of EGFR/MEK/ERK signaling pathway in hepatocellular carcinoma. 26386721 2016
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.020 Biomarker phenotype BEFREE Together, our results obtained both in vivo and ex vivo suggested that activation of EGFR/MEK/ERK signaling pathway through PCDH-17 promotes metastasis in HCC. 26386721 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE Together, our results obtained both in vivo and ex vivo suggested that activation of EGFR/MEK/ERK signaling pathway through PCDH-17 promotes metastasis in HCC. 26386721 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 PosttranslationalModification group BEFREE Methylation-specific PCR was used to examine the methylation status of PCDH17 in 191 ccRCC tumors and matched paired adjacent noncancerous tissues. 26404644 2015
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 PosttranslationalModification disease BEFREE PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. 26404644 2015
CUI: C0279702
Disease: Conventional (Clear Cell) Renal Cell Carcinoma
Conventional (Clear Cell) Renal Cell Carcinoma 		0.020 PosttranslationalModification disease BEFREE PCDH17 methylation occurred more frequently and was associated with malignant clinicopathological characteristics and poor prognosis in ccRCC patients. 26404644 2015
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE We found that PCDH17 was frequently downregulated or silenced in 78% (7/9) of breast tumor cell lines, as well as 89% (32/36) of primary tumors. 27351130 2016
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 AlteredExpression disease BEFREE We previously identified PCDH17, encoding protocadherin 17, as a frequently methylated and downregulated tumor suppressor gene (TSG) in gastric and colorectal cancers. 27351130 2016
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.020 Biomarker phenotype BEFREE Thus, we found that PCDH17 functions as a tumor suppressor inhibiting Wnt/β-catenin signaling and metastasis in breast cancer but is frequently methylated in primary tumors which could be a potential biomarker. 27351130 2016
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.010 AlteredExpression disease BEFREE Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. 27351130 2016
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.010 AlteredExpression disease BEFREE Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter. 27351130 2016
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.010 Biomarker group BEFREE We found that PCDH17 was frequently downregulated or silenced in 78% (7/9) of breast tumor cell lines, as well as 89% (32/36) of primary tumors. 27351130 2016